Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Noscira, a company into researching and developing drugs for treating neurodegenerative diseases and a subsidiary of the Grupo Zeltia, has released the results from Phase IIa clinical trial of Nypta (Tideglusib) which demonstrated that the drug had positive results and was well tolerated in patients with Alzheimer’s disease (AD).
Subscribe to our email newsletter
Noscira claimed that Phase IIa trial, which was conducted at three centres in Germany considering an advice from experts at the European Medicines Agency (EMA), is the first clinical trial of Nypta (Tideglusib) on a group of Alzheimer’s patients.
The results showed that patients treated with Nypta (Tideglusib) in addition to an acetylcholinesterase inhibitor as base treatment showed a consistent improvement in four of the five clinical efficacy variables that were assessed: Mini Mental State Examination (MMSE), Alzheimer’s Disease Assessment Scale (ADAS-cog), Geriatric Depression State and Global Clinical Assessment. Those variables are cognitive-behavioural scales for confirming and quantifying a person’s mental state.
The improvement was more appreciable in the patients who attained the highest dose and the number of patients that showed stabilisation or improvement in the MMSE scale was significantly greater in the group treated with Nypta (Tideglusib).
Teodoro del Ser, director of clinical development at Noscira has presented the study results at the International Conference on Alzheimer’s Disease (ICAD), held in Honolulu (Hawaii).
In order for these results to be significant, they must be confirmed in a Phase IIb trial in which a larger group of patients are expected to be treated for one year.